drugset / Trial / NCT03988335

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT03988335

Phase 2 Completed 35 enrolled Aristea Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Timeline

Start
2019-02-13
Primary completion
2019-11-05
Completion
2019-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject VIMNERIXIN Small molecule 300 mg Oral